KSD-101 vaccine trial for EBV-related blood cancers
Part of Blood & lymphatic, Cancer, Infections clinical trials.
This early-phase trial studies KSD-101 (a vaccine treatment) for people whose blood cancers are linked to EBV and who have not responded or have relapsed after standard treatment. It may help your immune system better control the cancer, especially when other options have already been tried.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You (or your legal guardian) can freely sign the consent form.
- You are between ages 18 and 70, any sex.
- You have an EBV-related blood cancer that either did not respond to usual treatment or came back, or you choose vaccine treatment as a “backup” (salvage) option.
- You are well enough to do normal daily activities (ECOG 0 to 1).
- Your blood counts and organ tests (liver, kidneys, heart, and clotting) are within required limits.
- You have lymph node/skin areas where injections can be given.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new study treatment called KSD-101 for blood cancers linked to the Epstein-Barr virus (EBV) that have come back or not responded to other treatments. The goal is to see if it is safe and effective for people with these types of cancer.
This trial tests an experimental vaccine called KSD-101 for people with blood cancers or lymphomas linked to the Epstein-Barr virus. The vaccine aims to help your immune system fight the cancer or prevent it from coming back.
This trial tests a new cell therapy called KSD-101 for nasopharyngeal cancer that has not responded to standard treatments. The therapy is injected into your lymph nodes and works by boosting your immune system to fight the cancer.
This trial tests a new treatment (KSD-101) for nasopharyngeal cancer that has not responded to standard therapies. It aims to see if this treatment can help when other options have failed.
This trial tests an experimental cell therapy that targets cells infected with the Epstein-Barr virus (EBV). It is for patients with certain blood cancers or post-transplant lymph disorders caused by EBV that have not responded to standard treatments or who cannot receive them.
This is an early-stage study testing a new immune-based treatment for people with conditions caused by the Epstein-Barr virus (EBV), such as chronic active EBV or post-transplant lymphoproliferative disease. The study aims to see if the treatment is safe and can help control the disease.
Hear when a new EBV-associated Haematologic Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.